» Articles » PMID: 35038409

Success Rates of Botulinum Toxin in Different Types of Strabismus and Dose Effect

Overview
Publisher Elsevier
Specialty Ophthalmology
Date 2022 Jan 17
PMID 35038409
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To determine the effect of botulinum toxin in different types of strabismus and analyze its dose effect.

Design: This was an interventional clinical study performed in a tertiary care university hospital.

Methods: Eighty six patients treated with botulinum toxin for strabismus were included. Main outcome measures involved success of botulinum toxin, alignment change per unit of toxin, and dose effect on complications and outcomes.

Results: Success rates were 31% for infantile esotropia, 25% for partially accommodative esotropia, 61.5% for residual esotropia, 25% for third cranial nerve paralysis, 13.3% for sixth cranial nerve paralysis, 75% for Duane retraction syndrome, and 38.5% for nonaccomodative esotropia. Improvement in deviation size after botulinum toxin treatment was significant in patients with infantile esotropia (p = 0.001), residual esotropia (p = 0.001), and nonaccomodative esotropia (p = 0.03). Mean deviation change per 1 unit of toxin was 2.7 ± 2.4 prism diopters (PD) with a single injection and 2.1 ± 1.9 PD with multiple injections. A 3.32 PD of early deviation change with botulinum toxin corrected 1 PD of final deviation. Success rate was not correlated with age (r = 0.040, p = 0.8), sex (r = -0.083, p = 0.6), mean dose (r = -0.149, p = 0.35), or total dose (r = 0.165, p = 0.29) but was significantly correlated with deviation size (β = -0.077, p = 0.0001). Complications were not associated with the dose of botulinum toxin (p > 0.05).

Conclusions: Botulinum toxin has variable outcomes in different types of strabismus. Still, it reduces the deviation size in most patients, thus allowing for a smaller amount of subsequent muscle surgery. Early overcorrection is a more powerful indicator of better outcome than postinjection duction deficit.

Citing Articles

Long-term efficacy of botulinum toxin for treatment of acquired non-accommodative comitant esotropia.

Kang M, Park J, Yang H, Hwang J Sci Rep. 2025; 15(1):5789.

PMID: 39962163 PMC: 11833041. DOI: 10.1038/s41598-025-88809-4.


Five decades of the use of botulinum toxin in ophthalmology.

Leszczynska A, Nowicka D, Pillunat L, Szepietowski J Indian J Ophthalmol. 2024; 72(6):789-795.

PMID: 38317306 PMC: 11232847. DOI: 10.4103/IJO.IJO_1030_23.


Golden Indications and an Overview on the Use of Botulinum Toxin in Strabismus.

Ozkan S Turk J Ophthalmol. 2023; 53(6):377-385.

PMID: 38126705 PMC: 10750087. DOI: 10.4274/tjo.galenos.2023.37806.


Botulinum toxin augmented bilateral lateral rectus recession versus three muscles surgery in large-angle intermittent exotropia.

Mattout H, Fouda S, El-Haig W Int J Ophthalmol. 2022; 15(10):1665-1670.

PMID: 36262862 PMC: 9522556. DOI: 10.18240/ijo.2022.10.15.